Compare AMCX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCX | ENGN |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.5M | 379.3M |
| IPO Year | 2011 | N/A |
| Metric | AMCX | ENGN |
|---|---|---|
| Price | $9.62 | $8.57 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $6.50 | ★ $22.71 |
| AVG Volume (30 Days) | ★ 408.8K | 314.7K |
| Earning Date | 11-07-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,316,303,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.41 | $2.65 |
| 52 Week High | $10.60 | $11.14 |
| Indicator | AMCX | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 56.36 |
| Support Level | $9.59 | $7.57 |
| Resistance Level | $9.91 | $8.47 |
| Average True Range (ATR) | 0.37 | 0.64 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 61.85 | 63.69 |
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.